Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE: Adjuvant osimertinib after SBRT in unresected EGFR-mutated stage I–II NSCLC
ChiCTR2500111875Phase 2Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Shandong First Medical University. Primary endpoint: Progression-free survival rate. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111875.